GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSKDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 9, 2026 | $0.45 | 2026-05-15 | 2026-05-15 |
| April 9, 2026 | $0.48 | 2026-02-20 | 2026-02-20 |
| January 8, 2026 | $0.43 | 2025-11-14 | 2025-11-14 |
| October 9, 2025 | $0.43 | 2025-08-15 | 2025-08-15 |
| July 10, 2025 | $0.43 | 2025-05-16 | 2025-05-16 |
Dividends Summary
- Consistent Payer: GSK plc American Depositary Shares (Each representing two Ordinary Shares) has rewarded shareholders with 94 dividend payments over the past 23 years.
- Total Returned Value: Investors who held GSK shares during this period received a total of $46.05 per share in dividend income.
- Latest Payout: The most recent dividend of $0.45/share was paid 9 days ago, on July 9, 2026.
- Yield & Schedule: GSK currently pays dividends quarterly with an annual yield of 3.47%.
- Dividend Growth: Since 2003, the dividend payout has grown by 59.6%, from $0.29 to $0.45.
Company News
The American Kidney Fund (AKF) has launched an online educational course on lupus nephritis through its Kidney Health Coach program to educate healthcare professionals and community members about symptoms, testing, diagnosis, and treatment. The course, developed with subject matter experts, aims to empower over 8,000 volunteer Kidney Health Coach...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and pro...
The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. Wh...
The global HPV vaccines market is projected to grow from USD 8.9 billion in 2025 to USD 18.4 billion by 2034, driven by rising HPV-associated cancer prevalence, expanding government immunization programs, and advancements in multivalent vaccines. North America leads the market with 41% share, while Asia-Pacific emerges as a significant growth con...
